Collecting and analyzing lung tissue samples from patients with non-small cell lung cancer
Official title: Molecular Fingerprinting of Lung Cancer
Run by Vanderbilt-Ingram Cancer Center · NCT00897117 · Data updated 2026-11-12
This study is trying to see if analyzing lung tissue samples from patients with non-small cell lung cancer can help predict how their tumors will behave and how well they might do after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | Vanderbilt-Ingram Cancer Center Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 3 sites (Nashville, Tennessee and 2 other locations) |
| Status | Recruiting |
| Started | May 1, 2001 |
| Main results expected | May 31, 2031 |
| Study ends | May 31, 2031 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT00897117 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with resectable stage I or II non-small cell lung cancer who are undergoing surgical resection.
✕Probably not a fit
Patients who have received chemotherapy or radiotherapy prior to surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research focuses on collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer. The study aims to develop statistical and computational methods to model the relationships between protein and RNA expression data and clinical outcomes. By examining tissue samples, researchers will identify molecular features that may predict tumor behavior and correlate these findings with clinical data, such as recurrence and survival rates. The study involves multiple centers and utilizes advanced techniques like gene expression analysis and microarray analysis.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of lung cancer biology and the development of new biomarkers for better patient outcomes.
How similar studies have gone: Other studies have shown success in analyzing tumor tissue samples to identify biomarkers, making this approach promising but not entirely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria * Diagnosis of non-small cell lung cancer * Clinical stage I and II disease * Resectable disease and complete surgical resection planned * Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network * Tumor specimen samples must be available at resection Exclusion criteria * Chemotherapy before surgery * Radiotherapy before surgery
Where it's running
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States Recruiting -
Dan Rudy Cancer Center at Saint Thomas Hospital
Nashville, Tennessee, United States Completed -
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States Suspended
Study contacts
- Principal investigator: Eric Grogan, MD — Vanderbilt Medical Center
- Study coordinator: VICC Clinical Trials Information Program
- Email: cip@vumc.org
- Phone: 800-811-8480
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.